Skip to Content

Press Releases

Press Releases

Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
Jan 04, 2023
Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab
Jan 03, 2023
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022
Dec 29, 2022
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022
Dec 27, 2022
Tiziana to Participate in January Investor Meetings
Dec 16, 2022
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
Dec 15, 2022
Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements
Dec 14, 2022
Tiziana Life Sciences Announces Date of Annual General Meeting 2022
Dec 06, 2022
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects
Nov 23, 2022
Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)
Nov 10, 2022
Displaying 1 - 10 of 423